TABLE 1.
Drug delivery using nanoparticles for lung cancer treatment.
| Polymeric nanoparticles | Application | Size | Drug | Main materials | Testing model/cell lines | Method and special features | Ref |
|---|---|---|---|---|---|---|---|
| PTX/PCEC nanoparticles | Antineoplastic agent | 168 nm | Paclitaxel | PCL-PEG-PCL, PCEC | A549 cells | A thin film dispersion method. In this work, a passive targeting paclitaxel-loaded nanoparticles (PTX-NPs) was prepared and used to evaluateits synergistic anti-tumor effect by combination with circadian chronomodulated chemotherapy in xenografted human lung cancer | Hu et al. (2017) |
| PGSC-PTX NPs PGSC-PTX@RBCm NPs | Inhibiting tumor growth | Average sizes about 50 nm and 100 nm | Paclitaxel (PTX) | PGSC | NCI-H460 cell line BABL/C nude mice | The emulsification-solvent evaporation method, by using erythrocyte membrane (RBCm) packaging and pH-sensitive technology, pH-sensitive polyethylene nanoparticles (L-γ-glutamyl carbocysteine) -paclitaxel (PGSC-PTX) (PGSC-PTX @ RBCm NPs) was prepared | Gao et al. (2017) |
| CSAC and CAP NPs | Carrier | Ranged from 124 nm to 195 nm and aggre-gated up to 195 nm | 5-Fluorouracil (5-FU) | Chondroitinsul-fate tailored cellulose acetate phthalate (CSAC) core shield nanoparticles (NPs) | A549 cancer cell line | Nano- precipitation The CSAC NPs loaded with 5-FU with small particle size were obtained using the nano- precipitation method with a high effect of trapping 5-FU | Garg et al. (2019) |
| TiO x /DOX NPs | A light activated drug carrier | 200 nm | Doxorubicin (DOX) | Titanium peroxide (TiOx) nanosheets | A549 cells | Measuring the viabilities of A549 cells investigate the chemotherapy performance, which incubated with free DOX, TiO2/DOX and TiOx/DOX. For 48 h cells include free DOX and nanocomposites were incubated | Dai et al. (2018) |
| SCND-SIS3 | Self-carried nanodrug | 280 nm | Smad3 (SIS3) | A self-carried nanodrug-SIS3 (SCND-SIS3) | Lewis Lung Cancer (LLC) mouse model, TGF-β/Smad3-dependent immunoregulatory landscape in NK cells | This NPs based on the reprecipitation method, which largely has an ability to increase solubility and bioavailability while decreases its nephrotoxicity | Lian et al. (2022) |
| Abraxane (Nanoparticle Albumin-Bound Paclitaxel) | Carrier | 130 nm | Paclitaxel incorporated | Albumin nanoparticles | Antigen presenting cells (APCs) non-small-cell lung cancer patients (NCT02367781, IMpower130) | The main mechanism of paclitaxel for cancer therapy includes microtubule stabilization. It can block cell division at the G2/M phase | Shi (2020) |